Cinnamon supplements (powder or extract capsules — not the spice on food) produce statistically significant but small reductions in glycemic surrogates in patients with type 2 diabetes (T2D) or polycystic ovary syndrome (PCOS). The effect is largest on fasting glucose, essentially trivial on HbA1c (-0.10%), thinly-evidenced on insulin/HOMA-IR, and there is no evidence at all on a patient-important outcome (CV events, complications, mortality) and no safety appraisal in the source. The source’s own framing is an add-on, not a replacement: «Cinnamon can be used as an anti-diabetic agent and an add-on treatment to control some glycemic indices among T2D patients and women with PCOS» (Zarezadeh et al., 2023). For the decision, this is a ceiling-is-a-finding result — a small, uncertain, surrogate-only lever that is dominated by established diabetes levers -> Layer 1 - Ranking Interventions for a Stratum.
The pooled estimates (umbrella MA of 11 interventional meta-analyses of RCTs)
Zarezadeh 2023 pooled 11 meta-analyses of RCTs (7 in T2D, 3 in PCOS, 1 metabolic syndrome; published 2008-2021), reporting both weighted (WMD) and standardized (SMD) mean differences vs placebo/control (Zarezadeh et al., 2023):
| Outcome | WMD (95% CI) | SMD (95% CI) | n MAs pooled | I2 | State |
|---|---|---|---|---|---|
| Fasting plasma glucose | -10.93 mg/dL (-16.22, -5.65) | -0.86 (-1.19, -0.52) | 6 | 66% (high) | benefit (surrogate) |
| HbA1c | -0.10% (-0.17, -0.03) | — | 7 (8 ES) | 28% (low) | small benefit (surrogate) |
| Insulin | -2.01 IU/mL (-3.96, -0.07) | -0.61 (-0.93, -0.30) | 3 | ~0% | thin benefit |
| HOMA-IR | -0.61 (-0.91, -0.31) | -0.78 (-1.26, -0.30) | 2 | ~0% | thin benefit |
All four endpoints are glycemic surrogates, not patient-important outcomes -> Surrogate Outcomes. The dose ranged 0.12-14.4 g/day (median 3.76 g/day), duration 4-52 weeks; AMSTAR quality rated 8 of 11 MAs high, 3 low (Zarezadeh et al., 2023).
The FPG / HbA1c discordance is the decision-relevant signal
The FPG drop looks large (-10.93 mg/dL; SMD -0.86, a “large” standardized effect) while HbA1c — which integrates ~3 months of glycemia and is far harder to game than a single fasting snapshot — barely moves (-0.10%). A fasting-glucose effect that does not translate into the integrated marker is exactly the pattern expected if the FPG signal is transient, non-durable, measurement-inflated, or heterogeneity-driven rather than a real shift in chronic glycemic burden (inferred from Zarezadeh et al., 2023). The high FPG heterogeneity (I2=66%) vs low HbA1c heterogeneity (I2=28%) is consistent with this. Weight the integrated marker (HbA1c) over the snapshot when they disagree -> Surrogate Outcomes.
The HbA1c benefit is fragile — most component MAs were individually null
The pooled HbA1c effect rests on a minority of the component meta-analyses. Four of the seven were individually null and one showed the opposite sign:
- «The other four meta-analyses by Allne et al., Deyno et al., Leach et al., and Baker et al., showed no statistically significant associations between cinnamon supplementation and HbA1c reduction» (Zarezadeh et al., 2023); Akilen 2012 reported an HbA1c increase (Table 1) (Zarezadeh et al., 2023).
- The pooled HbA1c effect concentrates in the large-sample and T2D strata: sample >=1000 -0.16% (-0.25, -0.06) vs <1000 -0.06% (-0.15, 0.03, NS); T2D -0.09% (-0.14, -0.05) vs non-T2D/PCOS “other” 0.01% (-0.51, 0.53, NS) (Zarezadeh et al., 2023).
So even where “significant,” the HbA1c effect is small and stratum-dependent — a benefit driven by a few large T2D pools, not a robust cross-study finding.
Umbrella non-independence — 11 MAs are not 11 independent estimates
The defining limitation of an umbrella-of-meta-analyses is that the included MAs pool overlapping sets of the same primary RCTs, so the “11 meta-analyses” are not 11 independent tests — the pooled umbrella estimate re-counts the same underlying trials across its inputs, and its precision is overstated relative to a single MA of the deduplicated trial set. Volume of reviews is not independence of evidence. The source does not flag this overlap (inferred from Zarezadeh et al., 2023) -> Rating Certainty of Evidence. The insulin and HOMA-IR arms are additionally thin on their own terms: «the included studies investigating the effects of cinnamon on insulin levels and HOMA-IR were not sufficient» (Zarezadeh et al., 2023).
The exposure is an isolate, and it is under-specified
This is cinnamon supplement (powder/extract), not cinnamon-as-spice in a meal — a different exposure (specify the exposure, not the label) -> Is the Food Category Doing Any Work. Worse, the supplement itself is heterogeneous: species vary across trials (Cassia, zeylanicum/verum/Ceylon, aromaticum, burmanii) and so does preparation:
- «the type of cinnamon and its prepration were different in the included studies, which might have affected the contents of active agents and their hypoglycemic activity» (Zarezadeh et al., 2023);
- «it is not clear whether both the extract and powder of cinnamon are equally effective» (Zarezadeh et al., 2023).
So “cinnamon lowers glucose” does not specify which cinnamon, in what form, at what dose — the active-agent content is unknown and the pooled effect averages over incommensurable products.
Dose-response — not estimable here
No dose-response curve can be read from this source: the authors «were not able to conduct subgroup analyses according to supplementation dosage and study duration» (Zarezadeh et al., 2023), because the included MAs did not report dose/duration consistently. A claimed dose-dependent insulin mechanism (Fig 6) is asserted, not shown as an estimated curve. No threshold, knee, plateau, or upper bound is locatable over the studied 0.12-14.4 g/day range; the median 3.76 g/day is a description of what was studied, not a target. A further stated confound: baseline biomarker differences across MAs «might have diluted the effect of cinnamon on glycemic control» (Zarezadeh et al., 2023).
Layer-1 sizing — a small, drug-dominated add-on
The marginal rock is small by construction. Cinnamon moves surrogates only, its most integrated surrogate barely (HbA1c -0.10%), and there is no patient-important-outcome evidence. In the broader diabetes domain, the dominant lifestyle and pharmacotherapy levers (intensive lifestyle modification, metformin) carry both larger effects and hard-outcome / incidence evidence -> Lifestyle vs Metformin for Diabetes Prevention (noting those DPP figures are prevention incidence, a different quantity than cinnamon’s within-patient surrogate deltas — not a numeric comparison, a ranking one). Net of the best realistic alternative a T2D patient could reach, cinnamon adds little; the source itself positions it as an add-on, not a substitute (inferred from Zarezadeh et al., 2023). Compare Resistant Starch and Glycemic Control — another small glycemic-surrogate add-on with the same ceiling profile. Reporting that this lever is small and uncertain is itself the decision-change: it licenses a reasonably-managed patient to not bother optimizing it.
Evidence states and the open gaps (G)
- Benefit (surrogate, moderate): fasting glucose reduction in T2D/PCOS — but heterogeneous and not mirrored in HbA1c.
- Small benefit / near-null (surrogate): HbA1c -0.10% — statistically significant, clinically trivial, fragile across component MAs.
- Insufficient evidence: insulin, HOMA-IR (source says the studies «were not sufficient»); durable glycemic change; dose-response; species/preparation head-to-head.
- Insufficient evidence — the load-bearing gap: no patient-important outcome (CV events, microvascular complications, mortality, quality of life) is measured. The whole evidence base is surrogate-only.
- Safety — unassessed here (G-gap). The source appraises efficacy and is silent on safety (0 mentions of coumarin; “adverse”/“safety” appear only in reference titles). This matters because Cassia cinnamon — used in several included MAs and the common commercial form — carries coumarin (hepatotoxicity / anticoagulant interaction) concern at the ~3.76 g/day median dose. A dedicated adverse-events SR exists and is cited but not folded in — acquire to appraise the net effect before any recommendation (inferred from Zarezadeh et al., 2023).
The loop is open. This page grades what the umbrella found and how confident to be in it; it does not grade whether cinnamon-takers were better off — no operation here checks a surrogate against a realized outcome.